Skip to main content
Premium Trial:

Request an Annual Quote

Alternative Computing

A number of startups are looking into alternative computing approaches, including DNA computing, to handle rising processing and storage demands, the Wall Street Journal reports.

A Boston-based startup called Catalog Technologies is pursuing DNA-based data storage, and according to the Journal, it relies on molecular biology tools to print synthetic molecules in which to store information and that the data can then be read by sequencing the sample and running it through a proprietary software program to return it to its original text, photo, or video form. The Journal adds that the firm recently showed it could store 14 gigabytes of data from Wikipedia within DNA molecules in a test tube.

Other companies, meanwhile, are exploring quantum computing and other approaches.

But these new approaches are "fraught with risk" for investors, Adam Fisher, a partner at Bessemer Venture Partners, tells the Journal. He notes that that's because they need new architectures. But still, his firm is looking to invest in quantum computing, it adds.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.